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ABSTRACT
Background: Adherence to the Mediterranean diet (Med-Diet) is
associated with a reduced risk of cardiovascular disease (CVD). How-
ever, the molecular mechanisms involved are not fully understood.
Objective: The objective was to compare the effects of 2 Med-Diets
with those of a low-fat diet on immune cell activation and soluble
inflammatory biomarkers related to atherogenesis in subjects at high
risk of CVD.
Design: In a controlled study, we randomly assigned 112 older sub-
jects with diabetes or 3 CVD risk factors to 3 dietary intervention
groups: Med-Diet with supplemental virgin olive oil (VOO),
Med-Diet with supplemental nuts, and low-fat diet. Changes from
baseline in cellular and serum inflammatory biomarkers were as-
sessed at 3 mo.
Results: One hundred six participants (43% women; average age: 68
y) completed the study. At 3 mo, monocyte expression of CD49d, an
adhesion molecule crucial for leukocyte homing, and of CD40,
a proinflammatory ligand, decreased (P , 0.05) after both Med-Diets
but not after the low-fat diet. Serum interleukin-6 and soluble in-
tercellular adhesion molecule-1, inflammatory mediators crucial in
firm adhesion of leukocytes to endothelial surfaces, decreased (P ,
0.05) in both Med-Diet groups. Soluble vascular cellular adhesion
molecule-1 and C-reactive protein decreased only after the Med-Diet
with VOO (P , 0.05), whereas interleukin-6, soluble vascular cel-
lular adhesion molecule-1, and soluble intercellular adhesion mole-
cule-1 increased (P , 0.05) after the low-fat diet.
Conclusions: Med-Diets supplemented with VOO or nuts down-
regulate cellular and circulating inflammatory biomarkers related
to atherogenesis in subjects at high risk of CVD. The results support
the recommendation of the Med-Diet as a useful tool against
CVD. Am J Clin Nutr 2009;89:248–56.
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death
and disability in industrialized countries, particularly in older
subjects, but incidence rates show marked geographic differences
(1). Some areas of the world, such as the Mediterranean coun-
tries and Japan, have CVD rates lower than those of countries in
Eastern and northern Europe and the United States (1, 2). A
factor frequently invoked to explain this health advantage in
southern Europe is customary adherence to the traditional Med-
iterranean diet (Med-Diet), which is characterized by an abundant
intake of vegetable products, a moderate consumption of fish and
wine, and a low intake of meat and dairy and industrial bakery
products (3). The cardioprotective effect of the Med-Diet has been
attributed to its ability to improve conventional risk factors, such
as adiposity, blood pressure, serum lipids, and insulin resistance
(4–8). However, alternative mechanisms, such as an antiinflam-
matory effect of the Med-Diet, have also been postulated (9).
Atherosclerosis has long been considered the result of lipid
accumulation in the artery wall; however, compelling evidence
now indicates that inflammation plays a key role at all stages of
the disease (10). Early phases of atherosclerosis involve the
recruitment of inflammatory cells from the circulation, their
adhesion to the endothelial surface, and their final migration
to the subendothelial space—a complex process mediated by
inflammatory stimuli that involves cytokine production and
up-regulation of adhesion molecules on endothelial cells and
circulating peripheral blood mononuclear cells (PBMCs) (11).
Ongoing inflammation is also crucial in the development of
instability and rupture of atheromatous plaques and the sub-
sequent appearance of ischemic events in advanced stages of the
disease (10, 11).
The important role of inflammation in the pathogenesis of
atherosclerosis has led to the belief that dietary preventive
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mèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain (ER); and
CIBER Fisiopatologı́a de la Obesidad y Nutrición (CIBEROBN), Instituto de
Salud Carlos III, Spain (ES, MV-A, MF, RC, RML-R, FM, ER, and RE).
2 Supported by grants from the Spanish Ministries of Education (AGL2004-
08378-C02-01, AGL 2005-05597ALI, and AGL2006-14228-C03-01/ALI) and
Health (PI04/1837, PI05/1519, G03/140, and RTIC RG06/045) and Centro
Nacional de Investigacı́on Cardiovascular (CNIC06).
3 Address reprint requests and correspondence to R Estruch, Department
of Internal Medicine, Hospital Clinic, Villarroel, 170, 08036 Barcelona,
Spain. E-mail: restruch@clinic.ub.es.
Received March 4, 2008. Accepted for publication September 12, 2008.
First published online December 3, 2008; doi: 10.3945/ajcn.2008.26094.





































measures act in part by modifying related inflammatory path-
ways (9). Indeed, results from cross-sectional studies (12, 13)
and feeding trials (7, 8) in Mediterranean populations suggest
that the Med-Diet has antiinflammatory effects, as was also
ascertained in a cross-sectional evaluation of the Nurses’ Health
Study (14). The effects of the Med-Diet on the expression of
adhesion molecules in PBMCs, a crucial step for their firm ad-
hesion to endothelial cells in the initial inflammatory events
of atherogenesis (10, 11), has not been previously investigated.
In a substudy of a larger clinical trial designed to compare the ef-
fects of 2 Med-Diets, one supplemented with virgin olive oil (VOO)
and another supplemented with mixed nuts, with those of a low-fat
diet on cardiovascular outcomes (PREDIMED Study) (8), we
evaluated changes in serum inflammatory markers and adhesion
molecule expression in circulating T lymphocytes and monocytes
from subjects at high-risk of CVD at 3 mo.
SUBJECTS AND METHODS
Subjects and design
The PREDIMED (PREvención con DIeta MEDiterránea)
Study is a parallel-group, multicenter, randomized, controlled
clinical trial of 4-y duration aimed to assess the effects of the
Med-Diet on the primary prevention of CVD (www.predimed.
org; ISRCTN35739639) (8).
We selected 112 potential participants in primary care centers
affiliated with the Hospital Clı́nic of Barcelona. Eligible par-
ticipants were community-dwelling men aged 55–80 y and
women aged 60–80 y who were free of CVD and met 1 of 2
criteria: type 2 diabetes or 3 of the following risk factors:
smoking, hypertension (blood pressure 140/90 mm Hg or
treatment with antihypertensive drugs), LDL-cholesterol con-
centration160 mg/dL (or treatment with hypolipidemic drugs),
HDL-cholesterol concentration 40 mg/dL, body mass index (in
kg/m2) 25, or family history of early-onset coronary heart
disease. Exclusion criteria were a history of prior CVD, any
severe chronic illness, drug or alcohol abuse, history of allergy
or intolerance to olive oil or nuts, or low predicted likelihood of
changing dietary habits according to the stages of change model.
Of the eligible candidates who met entry requirements, 97%
agreed to participate and provided informed consent to a pro-
tocol approved by our institutional review board.
Participants were randomly assigned into 3 diet groups:
a recommended low-fat diet and 2 Med-Diets, supplemented with
either VOO or mixed nuts. At baseline and 3 mo, participants
completed a 137-item validated food-frequency questionnaire
and a 14-item questionnaire assessing adherence to the Med-Diet,
recorded medication use, had an evaluation of physical activity,
and underwent various tests, including anthropometric and blood
pressure measurements and collection of fasting blood and a spot
urine sample, as previously described in detail (8). Main outcome
measurements were 3-mo changes in adhesion molecules and
CD40 expression by circulating PBMCs and plasma concen-
trations of inflammatory biomarkers.
Diets
The same dietitian delivered the intervention to the 3 groups.
All participants received personalized dietary advice about the
desired frequency of intake of specific foods during a 30-min
session. We advised participants allocated to the low-fat diet to
reduce intake of all types of fat and gave them a leaflet with written
recommendations according to American Heart Association
guidelines (15). For total fat intake, these recommendations were
opposite those given to participants in the 2 Med-Diet groups,
who received instructions to increase intake of vegetable fats and
oils. In the Med-Diet groups, intervention was based on individual
and group education, with a single group session scheduled 1 wk
after recruitment with up to 20 participants per session. At this
meeting, the dietitian gave advice to follow the recommended
Med-Diet and provided written material with elaborate descrip-
tions of target foods and seasonal shopping lists, meal plans, and
cooking recipes. The recommendations for the Med-Diet groups
included use of abundant olive oil for cooking and dressing; in-
take of 2 servings/d of vegetables and 3 servings/d of fresh
fruit; intake of 3 servings/wk of legumes, nuts, and fish or
seafood (1 serving of fatty fish); select white meats instead of
red or processed meats; and cooking at least twice a week with
garlic, onion, and tomato sauce simmered in olive oil. Advice
was also given to eliminate or limit the consumption of cream,
butter, margarine, cold meat, pâté, duck, sweetened beverages,
pastries, industrial bakery products, fried snacks, and out-of-
home precooked meals. All diets were ad libitum.
Participants allocated to the 2 Med-Diets also received free
provisions of typical Mediterranean foods. Depending on group
assignment, they were given a 3-mo allotment of either VOO (1
L/wk) or mixed nuts (30 g/d, as 15 g walnuts, 7.5 g almonds, and
7.5 g hazelnuts). The fatty acid composition of the olive oil and
nuts used in the trial is shown in Table 1. We estimated energy
and nutrient intakes from Spanish food-composition tables, as
described (8).
Clinical and laboratory measurements
Anthropometric and blood pressure measurements were per-
formed with standardized methods (8). Samples of serum, ED-
TA-plasma, and urine were coded and stored at 280C until
assay. A technician blinded to group allocation processed
PBMCs on the same day of blood extraction. Cells were ob-
tained from EDTA-venous blood over a 1.077 g/mL density
solution made of 9.1% (wt:vol) sodium diatrizoate and 5.7%
(wt:vol) polysaccharide and submitted to density-gradient
centrifugation (Lymphoprep; Axis-Shield PoC AC, Oslo, Nor-
way). Adhesion molecule expression on T lymphocytes and
monocytes was determined by using a double-direct immuno-
fluorescence test with fluorescein and phycoerythrin-coupled
monoclonal antibodies. The negative control was immunoglob-
ulin G mouse isotype conjugated with fluorescein and phyco-
erythrin. We used the following monoclonal antibodies, all
conjugated to phycoerythrin or fluorescein as appropriate:
anti-CD49d (Cytogmos, Barcelona, Spain), anti-CD11a (Bender
Medsystems, Vienna, Austria), anti-CD11b (Bender), and anti-
CD40 (Caltag, Burlingame, CA). Anti-CD14 (Caltag) and anti-
CD2 (Caltag) monoclonal antibodies were used to identify
monocytes and T lymphocytes, respectively. We treated PBMCs
with saturating amounts of monoclonal antibodies for 1 h at 4C
and then washed them with phosphate-buffered saline contain-
ing 2% fetal calf serum. We gated lymphocytes and monocytes
electronically by the forward and sidelight scatter pattern on
a FACSCalibur Clinical Cytometer (Becton-Dickinson, San





































Jose, CA) with the use of CellQuest software. We collected data
from a minimum of 2000 events (cells) gated as monocytes and
5000 events gated as lymphocytes based on side scatter and
forward scatter criteria. Results are expressed as mean fluores-
cence intensity (MFI) in arbitrary units (16).
Enzyme-linked immunosorbent assays were performed per
participant in thawed plasma with commercial kits (BLK, Bar-
celona, Spain) for soluble E-selectin, P-selectin, vascular cell
adhesion molecule 1 (sVCAM-1), intercellular adhesion mole-
cule 1 (sICAM-1), and the cytokine interleukin-6 (BLK and Elast
Amplification System; PerkinElmer Life Sciences, Boston, MA).
Additional serum analytes determined were as follows: fasting
glucose and immunoreactive insulin, with calculation of insulin
resistance in nondiabetic participants by using the homeostasis
model assessment (HOMA) method (insulin resistance ¼ fasting
insulin 3 fasting glucose/22.5, where insulin is in lU/mL and
glucose is in mmol/L); total cholesterol, triglycerides, and HDL and
LDL cholesterol; and high-sensitivity C-reactive protein (CRP), as
described previously (8). In a random sample of 56 participants
(53%), we measured urinary tyrosol and hydroxytyrosol concen-
trations by gas chromatography–mass spectrometry as markers of
adherence to VOO intake (17). The plasma fatty acid composition
was determined by gas chromatography, and the a-linolenic acid
(ALA) content was used as a measure of adherence to nut (walnut)
intake. For all laboratory methods, intra- and interassay CVs
ranged from 1.8% to 8.9% and from 0.9% to 9.9%, respectively.
Statistical analyses
For a parallel design, statistical power calculations indicated
that to detect mean differences of 10 MFI in monocyte CD49d
expression with a conservative SD of 10 MFI, assuming a
maximum loss of 10% participants, 21 subjects per group would
need to complete the study (a risk¼ 0.05; power¼ 0.8) (ENE 2.0
statistical program; GlaxoSmithKline, Brentford, United Kingdom).
CD49d expression was used to set sample size, but changes in
all endpoints were of equal interest in this study.
We used descriptive statistics with means and SDs for the
baseline characteristics of the participants. We transformed
variables with a skewed distribution (inflammatory molecules) to
their natural logarithm for analyses. One-factor analysis of
variance or chi-square tests, as appropriate, were used to de-
termine differences in baseline characteristics between the 3
study groups. Changes in all outcomes were assessed with re-
peated-measures analysis of variance for the 2 factors diet and
time and their interactions. Significant interactions were analyzed
by the simple effects test with multiple contrasts of Bonferroni.
Within- and between-group differences are expressed as means
and 95% CIs. All statistical tests were 2-tailed, and the signifi-
cance level was set at P , 0.05. Analyses were performed by
using SPSS (version 12.0; SPSS Inc, Chicago, IL).
RESULTS
Participant’s characteristics and self-selected diets
We excluded 6 of 112 presumably eligible participants before
randomization, 3 of whom declined to participate and 3 who did
not meet inclusion criteria. The baseline characteristics of the 106
participants who entered the study are shown in Table 2. By
study design, participants were mostly overweight subjects with
a sizeable burden of CVD risk factors, which were well balanced
among groups. No changes in medication use were made during
the study period. One subject withdrew from the study because
of intolerance to nuts. No other adverse effects were noted.
The self-selected dietary habits of the participants before the
study began were similar between the 3 intervention groups and
were close to those of the typical Med-Diet in several aspects:
high mean intakes of olive oil, vegetables, fruit, cereals, and fish;
moderate intakes of nuts, legumes, and alcoholic beverages; and
low intakes of industrial bakery products and sweets (Table 3).
Dietary habits deviated from the traditional Med-Diet, however,
because of high mean intakes of meat and dairy products.
As shown in Table 4, the baseline diets were high in total fat
and monounsaturated fatty acids (MUFAs), which was attributed
in part to the customary use of olive oil. For the same reason (ie,
low intake of vegetable fats other than olive oil or nuts), the total
polyunsaturated fatty acid content of the diet was relatively low,
whereas the proportion of marine n23 fatty acids was high
because of frequent fish intake.
Changes in food and nutrient intake
After 3 mo, intakes of VOO and nuts were higher in the re-
spective Med-Diet groups than in the low-fat-diet group or the
other Med-Diet group. VOO intake was lower in the low-fat-diet
group than in either Med-Diet group (Table 3). Legume intake
increased and cereal intake (mostly from white bread, which is
customarily eaten by Mediterranean populations) decreased in
all groups. No significant changes were observed in intake of
other foods or in energy expended in physical activity. Objective
measures of compliance confirmed food-frequency question-
naire data regarding intake of supplemental foods. At 3 mo,
urinary tyrosol increased by 18 ng/mL (95% CI: 0.22, 36) from
a baseline value of 28.9 6 25.8 ng/mL (P ¼ 0.047) and hy-
droxytyrosol increased by 99 ng/mL (95% CI: 5, 195) from
a baseline value of 101.8 6 110.0 ng/mL (P ¼ 0.037) in the
Med-Diet with VOO group. In this group, the mean plasma oleic
TABLE 1
Fatty acid composition of virgin olive oil and nuts used in the trial1
Olive oil Walnuts Almonds Hazelnuts
Total fat (%) 100 62.9 6 0.3 50.2 6 0.2 53.2 6 0.3
Palmitic acid (% of total) 8.2 6 0.2 6.3 6 0.0 7.4 6 0.1 7.4 6 0.1
Stearic acid (% of total) 3.2 6 0.1 2.6 6 0.0 1.8 6 0.0 1.9 6 0.1
Oleic acid (% of total) 75.0 6 0.8 14.0 6 0.3 61.2 6 0.4 72.1 6 0.2
Linoleic acid (% of total) 6.8 6 0.2 61.3 6 0.4 26.7 6 0.2 13.3 6 0.2
a-Linolenic acid (% of total) 0.4 6 0.0 14.3 6 0.1 0.1 6 0.0 0.8 6 0.0
1 Values are means 6 SDs of 6 measurements of random samples from different lots. Adapted from reference 8.





































acid content increased by 2.3 mol% (95% CI: 0.37, 4.24; P ¼
0.023) from a baseline value of 25.3 6 3.0 mol%. Increases in
urinary phenolics were observed in 18 of 19 participants, which
indicated 95% compliance. In participants allocated to the Med-
Diet with nuts group, the baseline plasma ALA content was
0.27 6 0.07 mol%, which increased 0.09 mol% (95% CI: 0.03,
0.14; P ¼ 0.005). Plasma ALA increased in 17 of 18 participants
(95% compliance). In the low-fat-diet group, the baseline
plasma oleic acid content of 27.4 6 4.6 mol% decreased by
2.07 mol% (95% CI: 23.58, 20.56; P ¼ 0.014). Increments in
urinary phenolics and the plasma oleic acid content observed in
the Med-Diet with VOO, as well as the increased plasma ALA
concentration in participants assigned to the Med-Diet with nuts
group, were all significantly different compared with the
changes observed in the low-fat-diet group (P , 0.05 for all).
The 14-point Med-Diet score was higher in the 2 Med-Diet
groups than in the low-fat-diet group (Table 3). Baseline values and
3-mo changes in energy and nutrient intakes are shown in Table 4.
No between-group differences were observed at baseline. At 3 mo,
MUFA intake was higher in the Med-Diet with VOO group than
in the low-fat-diet group. Participants assigned to consume the
Med-Diet with nuts had higher total fat and polyunsaturated fatty
acid intakes from supplemental nuts than did those assigned to the
low-fat diet and Med-Diet with VOO groups, respectively. No
major nutrient changes were observed in the low-fat-diet group.
Adhesion molecule and proinflammatory ligand CD40
expression on PBMCs
Immune cell adhesion molecule and CD40 expression were
similar at baseline in the 3 intervention groups (Table 5). Al-
though T lymphocyte CD49d expression decreased from base-
line in the 2 Med-Diet groups at 3 mo, no differences in changes
between groups were observed (Figure 1A). After the Med-Diet
with VOO, monocyte CD49d and CD40 expression were down-
regulated by 19% and 8%, respectively. In participants allocated
to the Med-Diet with nuts group, monocyte CD49d and CD40
expression were also decreased by 22% and 7%, respectively.
The changes in monocyte CD49d expression after the Med-Diet
with VOO were significantly different from those observed in the
low-fat-diet group, whereas the changes in CD40 expression ob-
served after the Med-Diet with nuts significantly differed from those
in the low-fat-diet group (Figure 1B). Monocyte CD11b expression
decreased from baseline in the 2 Med-Diet groups, but the changes
did not differ from those observed in the low-fat-diet group.
Some participants were under stable treatment with CVD risk–
reducing agents with known antiinflammatory properties, such as
angiotensin-converting enzyme (ACE) inhibitors and statins (18,
19). Thus, 36 participants used ACE inhibitors: 34 used statins
and 55 used both agents. Adhesion molecule and CD40 re-
sponses in both T lymphocytes and monocytes were similar
regardless of drug treatment (data not shown).
Circulating inflammatory biomarkers
Baseline plasma concentrations of inflammatory biomarkers
were similar between groups (Table 5). After the intervention
period, sICAM-1 and interleukin-6 decreased in both Med-Diet
groups and increased in the low-fat-diet group, whereas
sVCAM-1 and CRP decreased only in the Med-Diet group
given VOO (Figure 2). The level of sVCAM-1 also increased
in the low-fat-diet group. Interestingly, the changes in plasma
sVCAM-1 in the Med-Diet with VOO group correlated weakly
but significantly with those of the urinary concentration of ty-
rosol—a measure of VOO intake (r ¼ 20.255, P ¼ 0.019).
Changes in inflammatory biomarkers were independent of
treatment with ACE inhibitors or statins, except for the
sVCAM-1 concentration, which decreased only in participants
allocated to the Med-Diet with nuts group who were not using
ACE inhibitors (P ¼ 0.004). Platelet and leukocyte count were
also monitored, but only a nonsignificant decrease in white cell
count was observed in the Med-Diet plus VOO group.
TABLE 2
Participant’s characteristics1
Med-Diet with VOO (n ¼ 35) Med-Diet with nuts (n ¼ 35) Low-fat diet (n ¼ 36) P2
Age (y) 66 6 113 66 6 7 69 6 6 0.22
Men [n (%)] 16 (45.7) 24 (68.6) 20 (55.6) 0.15
Family history of CHD [n (%)] 9 (25.7) 10 (28.6) 6 (16.7) 0.13
Current smokers [n (%)] 8 (22.9) 12 (34.3) 9 (25.0) 0.61
BMI (kg/m2) 28.0 6 2.9 27.8 6 3.2 28.4 6 4.0 0.81
BMI  25 kg/m2 [n (%)] 29 (82.9) 29 (82.9) 29 (80.6) 0.96
Type 2 diabetes [n (%)] 21 (60.0) 24 (68.6) 25 (69.4) 0.65
Hypertension [n (%)] 22 (62.9) 17 (48.6) 27 (75.0) 0.11
Dyslipidemia [n (%)] 24 (68.6) 23 (65.7) 23 (63.9) 0.92
Medications [n (%)]
ACE inhibitors 11 (31.4) 11 (31.4) 14 (38.9) 0.75
Diuretics 10 (28.6) 7 (20.0) 12 (33.3) 0.44
Other antihypertensive agents 10 (28.6) 13 (37.1) 14 (38.9) 0.62
Statins [n (%)] 13 (37.1) 13 (37.1) 8 (22.2) 0.30
Other lipid-lowering agents [n (%)] 4 (11.4) 1 (2.9) 2 (5.6) 0.33
Insulin [n (%)] 2 (5.7) 5 (14.3) 3 (8.3) 0.45
Oral hypoglycemic drugs [n (%)] 12 (34.3) 15 (42.9) 20 (55.6) 0.19
Aspirin or antiplatelet drugs [n (%)] 4 (11.4) 4 (11.4) 5 (13.9) 0.94
1 Med-Diet, Mediterranean diet; VOO, virgin olive oil; CHD, coronary heart disease; ACE, angiotensin-converting enzyme.
2 From Pearson’s chi-square test for categorical variables and one-factor ANOVA for continuous variables.
3 Mean 6 SD (all such values).





































Cardiovascular disease risk factors
Changes in CVD risk factors were similar to those reported for
a larger PREDIMED cohort (8). Adiposity measures were es-
sentially unchanged from baseline at 3 mo. Systolic blood
pressure decreased by 5.64 mm Hg (95% CI: 210.49, 20.80;
P ¼ 0.023) and 28.81 mm Hg (95% CI: 213.00, 24.63; P ,
0.001) in the Med-Diet with VOO and nuts groups, respectively,
whereas diastolic blood pressure decreased 22.02 mm Hg (95%
CI: 23.89, 20.15; P ¼ 0.036) only in the Med-Diet with nuts
group. Fasting glucose (28.02 mg/dL; 95% CI: 214.40, 21.64;
TABLE 3
Consumption of key food items, physical activity, and 14-point Mediterranean diet score at baseline and 3 mo1
P2
Variable Med-Diet with VOO (n ¼ 35) Med-Diet with nuts (n ¼ 35) Low-fat diet (n ¼ 36) Time3 Group4 Interaction5
VOO (g/d)
Baseline6 14.0 6 21.57 8.1 6 11.3 8.3 6 14.4
0.035 ,0.001 0.006
Final 31.4 6 18.1a,8 11.3 6 13.6b 5.2 6 7.8b,8
Refined OO (g/d)
Baseline 23.5 6 18.2 20.2 6 15.3 25.6 6 14.8
0.004 0.82 0.53
Final 12.0 6 19.4 16.2 6 20.9 14.3 6 10.0
Total nuts (g/d)
Baseline 14.3 6 16.6 18.7 6 20.7 13.9 6 14.3
,0.001 ,0.001 0.001
Final 10.2 6 15.5a 49.2 6 21.4b,8 11.0 6 10.1a
Vegetables (g/d)
Baseline 342 6 141 320 6 114 307 6 169
0.368 0.063 0.309
Final 360 6 216 323 6 105 344 6 243
Legumes (g/d)
Baseline 21.6 6 17.5 17.9 6 10.0 20.1 6 10.9
0.006 0.834 0.526
Final 46.7 6 67.8 25.8 6 11.3 36.6 6 36.4
Fruit (g/d)
Baseline 253 6 120 253 6 97 208 6 95
0.062 0.626 0.31
Final 252 6 118 253 6 86 263 6 160
Cereals (g/d)
Baseline 274 6 119 300 6 108 258 6 109
,0.001 0.54 0.44
Final 241 6 119 259 6 107 233 6 101
Fish or seafood (g/d)
Baseline 93 6 56 87 6 42 70 6 28
0.141 0.619 0.107
Final 99 6 62 83 6 25 80 6 53
Meat or meat products (g/d)
Baseline 109 6 50 113 6 37 106 6 48
0.123 0.499 0.52
Final 92 6 35 97 6 45 102 6 60
Pastries, cakes, or sweets (g/d)
Baseline 22 6 8 21 6 8 20 6 7
0.359 0.156 0.345
Final 19 6 8 19 6 8 17 6 7
Dairy products (g/d)
Baseline 262 6 128 241 6 115 220 6 108
0.095 0.081 0.445
Final 257 6 125 225 6 118 223 6 131
Alcohol (g/d)
Baseline 14.1 6 15.9 12.1 6 34.2 13.1 6 14.5
0.62 0.906 0.481
Final 12.2 6 16.7 13.7 6 10.9 11.0 6 14.1
Wine (mL/d)
Baseline 69.9 6 102.9 50.7 6 79.4 64.1 6 103.4
0.414 0.807 0.626
Final 71.0 6 120.7 64.3 6 90.7 64.2 6 103.6
Physical activity (kcal/d)
Baseline 337.8 6 245.2 292.1 6 246.4 268.8 6 264.3
0.546 0.202 0.59
Final 328.1 6 243.3 256.5 6 200.3 306.2 6 242.2
Med-Diet score
Baseline 7.7 6 2.0 7.8 6 1.4 8.0 6 1.8
,0.001 ,0.001 ,0.001
Final 10.2 6 1.7a,8 10.1 6 1.8a,8 7.4 6 1.6b,8
1 Med-Diet, Mediterranean diet; VOO, virgin olive oil; OO, olive oil. Means within a row with different superscript letters are significantly different, P ,
0.05 (simple-effect analysis by Bonferroni’s multiple contrast).
2 Data analyzed by repeated-measures 2-factor ANOVA.
3 Comparison between before and after intervention.
4 Comparison between the 3 diet groups.
5 Comparison between measures obtained before and after intervention and between the 3 diet groups.
6 No significant differences between groups at baseline.
7 Mean 6 SD (all such values).
8 Significantly different from baseline, P , 0.04 (simple-effect analysis by Bonferroni’s multiple contrast).





































P ¼ 0.02) and the HOMA index decreased (20.86; 95% CI:
22.14, 20.03; P ¼ 0.008) in the Med-Diet with VOO group. In
addition, changes in serum glucose correlated with urinary
concentration of tyrosol in participants from this group (r:
20.314; P ¼ 0.036). HDL cholesterol increased by 5.18 mg/dL
(95% CI: 2.68, 7.67; P , 0.001) and 2.45 mg/dL (95% CI: 0.35,
4.60; P ¼ 0.024) in the Med-Diet with VOO and nuts groups,
respectively, whereas the cholesterol/HDL ratio decreased by
0.62 (95% CI: 20.92, 20.33; P ¼ 0.002) and 20.37 (95%
CI: 20.68, 0.07; P ¼ 0.023), respectively, in both Med-Diet
groups. No changes were observed in total cholesterol, LDL
cholesterol, or triglycerides for any group.
DISCUSSION
In this 3-mo dietary interventional trial, older subjects at high
risk of CVD who increased adherence to Med-Diets supple-
mented with VOO or mixed nuts showed reduced immune cell
activation and decreased concentrations of plasma inflammatory
biomarkers related to atherogenesis, and the changes were largely
independent of ongoing treatment with CVD risk–reducing
agents with antiinflammatory properties. This overall antiin-
flammatory effect of the Med-Diets combines with a reduced
potency of CVD risk factors and thus adds to the increasing
evidence for their cardioprotective role (6, 9, 20, 21). These
results contrast with those of participants advised to consume
a low-fat diet, in whom essentially no changes in immune cell
activation or conventional risk factors were observed, but in-
creases in plasma inflammatory markers occurred.
The beneficial effect of the Med-Diet against CVD has been
attributed to improved control of classic CVD risk factors (4–6,
20, 21). However, the knowledge that atherosclerosis is an in-
flammatory disease (10, 11) has stimulated research on the an-
tiinflammatory effects of the Med-Diet as another potential
TABLE 4
Baseline energy and nutrient intake and 3-mo changes1
Variables
Med-Diet with
VOO (n ¼ 35)
Med-Diet with
nuts (n ¼ 35)
Low-fat




Baseline6 2153 6 6407 2164 6 506 1869 6 571 0.503 0.154 0.392
Final 1979 6 651 2106 6 689 1807 6 761
Protein (% of energy)
Baseline 17.2 6 2.7 16.4 6 2.8 18.5 6 2.8 0.003 0.149 0.03
Final 17.8 6 3.2a,b 16.3 6 2.7a 19.3 6 4.0b,8
Carbohydrate (% of energy)
Baseline 43.8 6 6.5 43.1 6 7.4 44.7 6 7.1 0.007 0.757 0.88
Final 40.9 6 7.4 41.6 6 7.8 42.4 6 7.9
Total fat (% of energy)
Baseline 34.6 6 5.3 33.2 6 5.6 34.4 6 5.7 0.003 0.520 0.001
Final 35.6 6 6.7a,b 37.7 6 6.4a,8 34.2 6 5.7b
SFA (%)
Baseline 9.8 6 2.3 9.0 6 1.9 9.2 6 2.5 0.744 0.168 0.457
Final 9.6 6 2.5 9.0 6 2.3 9.4 6 2.7
MUFA (%)
Baseline 16.4 6 3.2 15.6 6 2.8 16.4 6 3.4 0.795 0.021 0.031
Final 17.6 6 4.1a,8 16.7 6 3.7a,b 15.5 6 3.1b
PUFA (%)
Baseline 5.8 6 2.2 5.6 6 1.9 6.2 6 2.2 0.028 0.001 ,0.001
Final 5.6 6 2.1a 8.7 6 2.1b,8 6.6 6 2.8a,b
a-Linolenic acid (g/d)
Baseline 1.6 6 1.1 1.5 6 0.9 1.3 6 0.7 ,0.001 ,0.001 ,0.001
Final 1.4 6 0.9a 2.6 6 0.7b,8 1.4 6 1.1a
Marine n23 fatty acids (g/d)
Baseline 0.95 6 0.5 0.82 6 0.5 0.8 6 0.4 0.043 0.443 0.044
Final 0.96 6 0.6a 0.84 6 0.5a 1.2 6 1.7b
Cholesterol (mg/d)
Baseline 450 6 117 437 6 115 392 6 122 0.939 0.530 0.272
Final 414 6 97 422 6 111 376 6 86
1 Med-Diet, Mediterranean diet; VOO, virgin olive oil; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated
fatty acids. Means within a row with different superscript letters are significantly different, P , 0.05 (simple-effect analysis by Bonferroni’s multiple
contrast).
2 Data analyzed by repeated-measures 2-factor ANOVA.
3 Comparison between before and after intervention.
4 Comparison between the 3 diet groups.
5 Comparison between measures obtained before and after intervention and between the 3 diet groups.
6 No significant differences between groups at baseline.
7 Mean 6 SD (all such values).
8 Significantly different from baseline, P , 0.04 (simple-effect analysis by Bonferroni’s multiple contrast).





































mechanism to explain its association with improved cardiovas-
cular outcomes (7, 8, 12, 13).
In our study, the supplemental foods provided to the 2 Med-
Diet groups accounted for most nutrient changes and thus might
be responsible in part for the observed antiinflammatory effects.
One of them was VOO, a paradigmatic Med-Diet food that is rich
in MUFA and antioxidant phenolics. Experimental and clinical
studies have shown that olive oil down-regulates endothelial
VCAM-1, ICAM-1, and E-selectin expression (22) and decreases
plasma concentrations of sICAM-1, sVCAM-1, sE-selectin, in-
terleukin-6, and CRP in high-risk patients (23–25). Another
supplemental food was mixed nuts, a classic Mediterranean food
rich in antioxidants, and walnuts, a good source of the plant-
derived n23 fatty acid ALA, as the major component. Frequent
intake of nuts has been associated with decreased concentrations
of interleukin-6, CRP, and fibrinogen in a population free of
CVD (26), whereas a Med-Diet supplemented with walnuts
decreased concentrations of sVCAM-1 in healthy and hyper-
cholesterolemic subjects (23, 27, 28). An ALA-rich Med-Diet
was shown to be very efficient for secondary prevention of
coronary events and death in the Lyon Diet Heart Study (20).
The recruitment and adhesion of PBMCs to the endothelium is
an early event in fatty streak formation in which adhesion
molecules and cytokines play a key role, followed by activation
of resident macrophages and lymphocytes to secrete additional
cytokines that in turn activate other cell types and lead to a self-
perpetuating inflammatory process in the vascular wall that is
instrumental in more advanced stages of atherosclerosis, such as
plaque growth, vulnerability, and rupture and leads to thrombosis
and acute ischemic events (10, 11). Inhibition of both cell-me-
diated and humoral inflammatory pathways, as shown in our
study, provides a molecular mechanism for an antiathero-
sclerotic effect of the Med-Diet diet. Interestingly, the changes
were opposite those observed after the recommended low-fat
diet that, given the small changes in nutrients from baseline, was
basically a control diet, similar to the Med-Diets except for the
VOO and nut supplements. Noticeably, the antiinflammatory
effects of the Med-Diets were essentially similar in subjects
under stable treatment with risk-reducing agents that have de-
monstrable antiinflammatory properties, namely ACE inhibitors
(18) and statins (19), and in those not treated with these drugs.
Thus, the antiinflammatory effect of the Med-Diet appears to be
complementary to that of pharmacologic treatment. Also, the
benefit of dietary change occurred in older individuals with
a sizeable burden of risk factors for CVD. This suggests that the
potential antiatherosclerotic effect of healthy foods is not limited
to early disease.
Although not explored in our study, a probable mechanistic
explanation for the observed effects lies in reduced oxidative
stress after high intakes of natural antioxidants present in the
supplemental foods. Constitutive adhesion molecule and cyto-
kine production with subsequent PBMC recruitment is low or
absent in normal vessels, but is significantly induced in ath-
erosclerosis by immune challenges, such as intimal retention of
oxidatively modified LDL (10). The redox-sensitive nuclear
transcription factor jB, the main signaling pathway for ex-
pression of genes encoding proinflammatory cytokines, is in-
hibited by phenolic antioxidants similar to those present in VOO
and nuts (29). A recent PREDIMED substudy indicated that the
2 Med-Diets were associated with a reduced oxidative status, as
shown by lower serum concentrations of oxidized LDL com-
pared with the low-fat diet (30).
Our study had limitations. One limitation related to our attempt
to ensure the participants’ compliance by providing dietary
instructions. In the Med-Diet groups, adherence to the supple-
mental foods provided was good, as determined by objective
TABLE 5
Baseline peripheral blood mononuclear cell expression of cell surface inflammatory mediators (adhesion molecules and CD40) and concentrations of
circulating inflammatory molecules1




CD11a 121 6 343 30 128 6 30 26 121 6 25 23 0.64
CD49d 19.7 6 6.3 23 19.2 6 3.8 22 19.6 6 6.7 21 0.96
CD40 6.0 6 2.1 28 5.9 6 1.9 22 5.9 6 2.2 22 0.98
Monocytes
CD11a 128 6 60 28 108 6 47 25 117 6 60 26 0.44
CD11b 51.5 6 20.0 29 43.9 6 12.4 24 46.6 6 17.8 25 0.26
CD49d 28.9 6 10.1 22 22.5 6 8.5 24 25.5 6 11.1 23 0.10
CD40 22.7 6 12.1 29 16.4 6 9.0 25 20.0 6 9.9 26 0.10
Circulating inflammatory
mediators
sE-selectin (ng/mL) 35.0 6 24.0 28 36.7 6 17.7 33 40.6 6 20.8 30 0.57
sP-selectin (ng/mL) 57.4 6 51.6 20 69.6 6 51.4 31 66.1 6 55.8 26 0.72
sVCAM-1 (ng/mL) 1033 6 311 33 962 6 363 28 1023 6 298 32 0.66
sICAM-1 (ng/mL) 290 6 104 33 270 6 113 28 239 6 103 32 0.16
Interleukin-6 (pg/mL) 6.8 6 4.6 33 6.8 6 6.0 24 5.9 6 5.3 32 0.73
CRP (mg/L) 4.0 6 4.9 31 2.2 6 1.9 27 2.8 6 2.7 27 0.15
1 Med-Diet, Mediterranean diet; VOO, virgin olive oil; MFI, mean fluorescence intensity (arbitrary units); sE-selectin, soluble E-selectin; sP-selectin, soluble
P-selectin; sVCAM-1, soluble vascular cell adhesion molecule 1; sICAM-1, soluble intercellular adhesion molecule 1; CRP, high-sensitivity C-reactive protein.
2 Differences between groups by one-way ANOVA.
3 Mean 6 SD (all such values).





































measurements, but participants allocated the low-fat diet did not
receive a personalized intervention and barely changed their
dietary habits. In fact, there were no significant changes in total
fat intake in the low-fat-diet group, probably because participants
belonged to a Mediterranean culture, where people prefer using
olive oil. However, because the recommended low-fat diet was
not the usual diet, participants in this group also changed food
habits in a healthy way. Thus, as noted, an important part of the
observed differences in outcomes might be attributed to sup-
plemental VOO and nuts. Also, a 3-mo period provides no in-
formation about the sustainability of the antiinflammatory effects
or their influence on incident CVD events. Our study also had
strengths, such as its design (controlled clinical trial), excellent
completion rates, good compliance with supplemental foods, and
the number of inflammatory biomarkers evaluated.
In conclusion, Med-Diets supplemented with VOO or nuts
reduce the potency of CVD risk factors and down-regulate
cellular and humoral inflammatory pathways related to athero-
sclerosis. That these beneficial effects are observed in older
subjects at high risk of CVD suggests that it is never too late to
change dietary habits to improve health status. The results
support recommendations to consume a Med-Diet as a useful tool
to prevent CVD.
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